Clinical Trial

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat

Study acronym: SUPREME-01
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-21; most recent amendment 2026-03-27.
Trial Details
NCT Number NCT07140939
Lead Sponsor Caliway Biopharmaceuticals Co., Ltd.
Conditions Subcutaneous Fat
Enrollment 300 participants
Start Date 2026-07
Primary Completion 2027-05 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-03-30